Yahoo Finance • 3 days ago
In trading on Wednesday, shares of Recursion Pharmaceuticals Inc (Symbol: RXRX) crossed above their 200 day moving average of $5.83, changing hands as high as $5.89 per share. Recursion Pharmaceuticals Inc shares are currently trading up... Full story
Yahoo Finance • 3 days ago
We came across a bullish thesis on Recursion Pharmaceuticals, Inc. on Emil Hartela Investing’s Substack by Emil. In this article, we will summarize the bulls’ thesis on RXRX. Recursion Pharmaceuticals, Inc.'s share was trading at $4.6300 a... Full story
Yahoo Finance • 12 days ago
Key Points The GPU leader continues to invest in AI-related companies. Its mere involvement with these businesses makes them worth a look for retail investors. 10 stocks we like better than Nvidia › You've probably heard that AI chip gia... Full story
Yahoo Finance • 13 days ago
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the stocks on Jim Cramer’s radar recently. When a caller asked about the stock during the lightning round, Cramer stated: “I don’t know. It’s been such a dog. It’s been a dog, we had... Full story
Yahoo Finance • 16 days ago
It’s a sign that’s impossible to ignore. As you soon as you pull up the Price Overview for Recursion Pharmaceuticals (RXRX [https://www.barchart.com/stocks/quotes/RXRX/overview]), you’re greeted with a clear message: Barchart’s Technical O... Full story
Yahoo Finance • 26 days ago
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the 12 Best NASDAQ Penny Stocks to Buy According to Hedge Funds. On September 10, Needham retained its Buy rating on Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), maintaining the pri... Full story
Yahoo Finance • last month
Key Points Nvidia's largest stock holding is CoreWeave, which has more than doubled since its March IPO. Changes in the prices of Nvidia's stock holdings have had a notable positive effect on its recent earnings. Nvidia's active investing... Full story
Yahoo Finance • 2 months ago
We recently published 10 Stocks Crash as AI Glow Fades. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of Wednesday’s worst performers. Recursion Pharmaceuticals dropped for a third straight day on Wednesday, slashing 6.29 percent to... Full story
Yahoo Finance • 2 months ago
Najat Khan, a Director and Chief R&D Commercial Officer at Recursion Pharmaceuticals (NASDAQ:RXRX), sold 36,599 shares of Class A Common Stock on August 18, 2025. The shares were sold at a price of $5.524, for a total value of $202,172.... Full story
Yahoo Finance • 2 months ago
Nvidia quietly buys more stock in AI infrastructure favorite originally appeared on TheStreet. Nvidia has been at the center of the artificial intelligence (AI) boom, supplying the chips that power everything from cloud data centers to ge... Full story
Yahoo Finance • 2 months ago
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), a $2.48 billion market cap biotech company, saw Chief Executive Officer Christopher Gibson sell 617,875 shares of Class A Common Stock on August 11, 2025, for approximately $3.26 million. The... Full story
Yahoo Finance • 2 months ago
Recursion Pharmaceuticals (NASDAQ:RXRX [https://www.chartmill.com/stock/quote/RXRX]) reported its second-quarter 2025 financial results, delivering a mixed performance relative to analyst expectations. The company, a clinical-stage biotech... Full story
Yahoo Finance • 2 months ago
SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and financial results for its second quarter... Full story
Yahoo Finance • 3 months ago
Key Points Artificial intelligence-powered drug development isn't a mere premise anymore. Recursion Pharmaceuticals has made it a reality. The next era of e-commerce favors platforms like Shopify's, which allows brands to connect with con... Full story
Yahoo Finance • 3 months ago
Rallybio (RLYB) announced that it has entered into a definitive agreement to sell its interest in REV102, an ENPP1 inhibitor in preclinical development for the treatment of patients with hypophosphatasia, to joint venture partner Recursion... Full story
Yahoo Finance • 3 months ago
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the 10 Stocks Crash Hard Alongside Wall Street. Recursion Pharmaceuticals dropped its share prices by 6.45 percent on Monday to close at $4.93 apiece as investors appeared to have bo... Full story
Yahoo Finance • 3 months ago
Salt Lake City, UT, July 08, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition of Rallybio’s (NASDAQ: RLYB) full interes... Full story
Yahoo Finance • 3 months ago
Investing.com -- Morgan Stanley initiated coverage on three AI-integrated biotechnology firms, Absci, Schrodinger (NASDAQ:SDGR), and Recursion Pharmaceuticals, flagging divergent business models and upcoming catalysts in a sector under pre... Full story
Yahoo Finance • 3 months ago
Investing.com - Morgan Stanley has resumed coverage of Recursion Pharmaceuticals (NASDAQ:RXRX) with an Equalweight rating and a $5.00 price target. According to InvestingPro data, the stock currently trades near its Fair Value, with anal... Full story
Yahoo Finance • 3 months ago
Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best AI stocks to buy according to hedge funds. Earlier on June 6, a significant advancement in drug discovery was announced with the open-source release of Boltz-2, which is a bio... Full story